| Control | LPS |
---|
NS | norNOHA (40mg/kg) | NS | norNOHA (20mg/kg) | norNOHA (40mg/kg) |
---|
HR (bpm) |
Baseline | 593±50 | 619±57 | 605±61 | 651±54 | 631±62 |
LMBO | 584±44 | 626±71 | 603±50 | 634±74 | 636±68 |
SAP (mmHg) |
Baseline | 93±18 | 97±11 | 96±14 | 95±7 | 102±4 |
LMBO | 91±12 | 77±7A* | 93±16* | 92±9 | 101±6 |
PAP (mmHg) |
Baseline | 17±2 | 17±1 | 18±2 | 16±2 | 17±1 |
LMBO | 19±1* | 19±1* | 20±1* | 19±4* | 20±2* |
QLPA (ml/min) |
Baseline | 2.3±0.3 | 2.6±0.5 | 2.8±0.4 | 2.9±0.9 | 2.4±0.3 |
LMBO | 1.4±0.2* | 1.9±0.5* | 2.3±0.4B* | 2.6±1.0AB | 1.6±0.3* |
- Hemodynamic parameters before (baseline) and during left mainstem bronchus occlusion (LMBO) in wild-type mice 22 h after challenge with saline (control) or endotoxin (LPS). One hour prior to the measurement, mice were treated with normal saline (NS) or with the arginase inhibitor Nω-hydroxy-nor-Arginine (norNOHA). N = 7 per group
- HR heart rate, SAP systemic arterial pressure, PAP pulmonary arterial pressure, QLPA flow rate in the left pulmonary artery, bpm beats per minute, mmHg millimeters of mercury, and ml/min milliliter per minute
- Data are presented as mean ± SD. A P < 0.05 vs. LPS norNOHA 40 mg/kg, B P < 0.05 vs. control NS, * P < 0.05 vs. baseline